Wall Street analysts released a slew of notable recommendations and upgrades this Thursday, impacting sectors ranging from technology to energy and consumer goods. Key moves included Bank of America reiterating its buy rating on Micron Technology (MU) amid a “durable memory cycle” driven by AI demand and supply-side discipline. Goldman Sachs upgraded TC Energy (TRP) to buy from neutral, citing an overdone selloff and favorable growth fundamentals. RBC initiated coverage of Digital Turbine (APPS) with an outperform rating, highlighting its OEM partnerships and expanding addressable market. Amazon (AMZN) was added to Goldman Sachs’ conviction buy list, with the firm noting its underperformance versus tech peers and structural tailwinds.
Wells Fargo upgraded BP (BP) to overweight from equal weight while downgrading Exxon (XOM) to equal weight, favoring BP’s upside potential. Goldman Sachs also upgraded Occidental Petroleum (OXY) to buy, emphasizing its advanced recovery strategy. JPMorgan initiated coverage of Kura Oncology (KURA) and Enliven Therapeutics (EMGN) with overweight ratings, citing promising oncology pipelines and favorable decarbonization trends. Mizuho upgraded BJ’s Restaurants (BJ) to outperform, raising its price target after strong same-store sales growth projections. UBS maintained its buy recommendation on Nvidia (NVDA), calling it an “exceptional wealth compounder” amid AI-driven growth.
Additional notable calls included Consolidated Edison’s (ED) upgrade to overweight by Wells Fargo, framed as a defensive play amid energy transition trends. Oppenheimer initiated Vita Coco (COCO) with an outperform rating, while JPMorgan highlighted Spyre Therapeutics (SYRE) as a compelling biotech opportunity. Roth initiated Civeo (CVEO) with a buy rating, citing structural demand for workforce accommodations. Loop upgraded Dollar Tree (DLTR) to buy, supported by favorable economic conditions. Morgan Stanley initiated Toll Brothers (TOL) with an overweight rating, underscoring resilient earnings and undervalued valuation. Analysts also turned bullish on Meta (META), Teva (TEVA), and Forbright (FBOK) amid strong earnings, pricing power, and rate-sensitive opportunities, respectively.
